Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
65.50    0.00 (0.00%)
Bid:
64.00
Ask:
67.00
Spread: 3.00 (4.688%)
Market Cap: £15.96m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

PFAS Contract Award

6 May 2025 07:00

RNS Number : 3470H
MyCelx Technologies Corporation
06 May 2025
 

 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

6 May 2025

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

PFAS Contract Award

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to announce the award of a short-term rental contract for a mobile PFAS treatment system to treat groundwater contamination at a site in North Dakota for the U.S. Department of Defense (DoD).

 

The original contract for PFAS treatment is for three months, but we believe volumes will increase so we are anticipating the rental potentially extending beyond the original term. As part of the project, MYCELX is conducting in-house treatability analysis to assess groundwater characteristics and predict system performance, enabling the Company to optimize PFAS removal efficiency on site. The ability to perform in-house treatability analyses accelerates sales timelines by giving MYCELX control over the testing process ultimately decreasing the amount of time to determine system design.

 

The contract is included in the Company's revenue forecasts for the 2025 financial year. It reflects the continued validation of MYCELX's innovative solutions by major clients with numerous sites, such as the DoD, who has assessed 718 sites to date and moved more than 50% to the next investigative phase which will require effective solutions such as MYCELX for long-term cleanups. According to the U.S. Government Accountability Office, remediation costs will continue to increase as the DoD learns more about the extent of PFAS releases. This is a decades long cleanup and working with the DoD now gives the Company more reference projects that can be promoted within the DoD as well as with other similar application projects.

 

Connie Mixon, CEO, commented:

 

"Working with the Department of Defense on this PFAS remediation project as a very positive step forward for MYCELX. We have focused significant time and resources on developing our offering in the PFAS remediation market and being selected for contracts with the DoD demonstrates that our systems are cost effective, high performing, and reliable. We will shortly be involved in two highly anticipated PFAS trials, which, if successful, have the potential to convert into further commercial sales contracts in due course. As a team, we are very excited about the U.S.EPA's recent notification of plans to support PFAS remediation in the U.S., which we believe will create urgency and confidence for decision makers to move on clean up timelines. We look forward to keeping all of our stakeholders updated on our progress over the remainder of 2025."

 

 For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Dan Hodkinson (Corporate Finance)

Ondraya Swanson (Corporate Broking)

Jasper Berry / Michael Johnson (Sales)

 

 

 

Tel: +44 20 7220 0500

 

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRGZGGKKKFGKZM
Date   Source Headline
16th Jun 202611:29 amRNSAnnual Financial Report
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.